Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · second_quarter · 2A
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Source: Senate LDA
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Consolidated Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
SUPPORT for Patients and Communities Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
SUPPORT for Patients and Communities Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
SUPPORT for Patients and Communities Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
SUPPORT for Patients and Communities Act
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
FDA Reauthorization Act of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
PIMA of 2017
Client: AMERICAN CLINICAL LABORATORY ASSN · Firm: AMERICAN CLINICAL LABORATORY ASSN
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · third_quarter · 3A
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · third_quarter · Q3
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157)
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services; P.L. 115-245 Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (H.R. 6157); H.R.6 SUPPORT for Patients and Communities Act; role of clinical laboratory services in treating, detecting and preventing opioid and chemical substance abuse, addiction, and diversion.
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · second_quarter · Q2
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy; Medicare physician signature documentation requirements; National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018 and FY2019; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018 and FY2019 (S3158); H.R.1625 Vehicle for Consolidated Appropriations Act 2018; Medicare reimbursement of clinical laboratory services
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (S 2852/HR 6378)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2018 · first_quarter · Q1
commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises and reauthorization of the Pandemic and All Hazards Preparedness Act
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · fourth_quarter · Q4
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · third_quarter · Q3
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · second_quarter · Q2
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; P.L. 115-30, Making further continuing appropriations for fiscal year 2017, and for other purposes; P.L. 115-31, Consolidated Appropriations Act, FY2017; P.L. 114-254 Further Continuing and Security Assistance Appropriations Act, 2017, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Acts, 2018; FY2018 White House Budget Proposal.
AMERICAN CLINICAL LABORATORY ASSN via AMERICAN CLINICAL LABORATORY ASSN
2017 · first_quarter · Q1
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
regulation and oversight of clinical laboratories, including laboratory developed test services; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises.
reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
regulation and oversight of clinical laboratories, including laboratory developed test services; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees; narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE